Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept in neovascular glaucoma surgery
ChiCTR2500112177Phase 4Completed
- Sponsor
- Department of Ophthalmology, Second Affiliated Hospital of Harbin Medical University
- Start
- Nov 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of conbercept in neovascular glaucoma (NVG) (2 arms), sponsored by Department of Ophthalmology, Second Affiliated Hospital of Harbin Medical University. Primary endpoint: Intraocular pressure (IOP). Started Nov 2025; status: completed.
02
Drugs
conbercept
03
Conditions
neovascular glaucoma (NVG)
Beyond the preview
Go deeper on ChiCTR2500112177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112177.